Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1993 1
2002 2
2006 2
2007 2
2009 2
2011 2
2012 2
2014 2
2015 6
2016 4
2017 7
2018 7
2019 6
2020 12
2021 12
Text availability
Article attribute
Article type
Publication date

Search Results

61 results
Results by year
Filters applied: . Clear all
Page 1
The heterodimer S100A8/A9 is a potent therapeutic target for idiopathic pulmonary fibrosis.
Araki K, Kinoshita R, Tomonobu N, Gohara Y, Tomida S, Takahashi Y, Senoo S, Taniguchi A, Itano J, Yamamoto KI, Murata H, Suzawa K, Shien K, Yamamoto H, Okazaki M, Sugimoto S, Ichimura K, Nishibori M, Miyahara N, Toyooka S, Sakaguchi M. Araki K, et al. Among authors: suzawa k. J Mol Med (Berl). 2021 Jan;99(1):131-145. doi: 10.1007/s00109-020-02001-x. Epub 2020 Nov 9. J Mol Med (Berl). 2021. PMID: 33169236
Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers.
Vojnic M, Kubota D, Kurzatkowski C, Offin M, Suzawa K, Benayed R, Schoenfeld AJ, Plodkowski AJ, Poirier JT, Rudin CM, Kris MG, Rosen NX, Yu HA, Riely GJ, Arcila ME, Somwar R, Ladanyi M. Vojnic M, et al. Among authors: suzawa k. J Thorac Oncol. 2019 May;14(5):802-815. doi: 10.1016/j.jtho.2018.12.038. Epub 2019 Mar 1. J Thorac Oncol. 2019. PMID: 30831205 Free PMC article.
Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of Resistance.
Yu HA, Suzawa K, Jordan E, Zehir A, Ni A, Kim R, Kris MG, Hellmann MD, Li BT, Somwar R, Solit DB, Berger MF, Arcila M, Riely GJ, Ladanyi M. Yu HA, et al. Among authors: suzawa k. Clin Cancer Res. 2018 Jul 1;24(13):3108-3118. doi: 10.1158/1078-0432.CCR-17-2961. Epub 2018 Mar 12. Clin Cancer Res. 2018. PMID: 29530932 Free PMC article.
Overcoming epithelial-mesenchymal transition-mediated drug resistance with monensin-based combined therapy in non-small cell lung cancer.
Ochi K, Suzawa K, Tomida S, Shien K, Takano J, Miyauchi S, Takeda T, Miura A, Araki K, Nakata K, Yamamoto H, Okazaki M, Sugimoto S, Shien T, Yamane M, Azuma K, Okamoto Y, Toyooka S. Ochi K, et al. Among authors: suzawa k. Biochem Biophys Res Commun. 2020 Aug 27;529(3):760-765. doi: 10.1016/j.bbrc.2020.06.077. Epub 2020 Jul 19. Biochem Biophys Res Commun. 2020. PMID: 32736704
The neutrophil-to-lymphocyte ratio as a novel independent prognostic factor for multiple metastatic lung tumors from various sarcomas.
Yamamoto H, Namba K, Yamamoto H, Toji T, Soh J, Shien K, Suzawa K, Kurosaki T, Otani S, Okazaki M, Sugimoto S, Yamane M, Takahashi K, Kunisada T, Oto T, Toyooka S. Yamamoto H, et al. Among authors: suzawa k. Surg Today. 2021 Jan;51(1):127-135. doi: 10.1007/s00595-020-02093-5. Epub 2020 Aug 3. Surg Today. 2021. PMID: 32747982
61 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page